Clozapine treatment for negative signs and cognitive impairment in schizophrenia

Kfir Feffer*, Inna Levin

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Early studies of the effect of clozapine on negative symptoms from the early 70‘s till mid 90‘s pointed an efficacy of the treatment on negative symptoms. These findings established clozapine as the only pharmacotherapy available for those patients. However, in recent more detailed studies clozapine had found to have limited or no added value to other antipsychotics. In contrast, clozapine effect on cognition seems to have mixed results. Recent evidence suggests that clozapine metabolites might have a role, specifically N-desmethylclozapine (NDMC). Treatment with clozapine potential for positive impact on cognition might be linked to the NDMC level rather than to the clozapine’s. In this chapter, we will describe the evidence for the effect of clozapine on negative symptoms and cognitive impairment in schizophrenia.

Original languageEnglish
Title of host publicationClozapine
Subtitle of host publicationMedical Uses, Interactions and Side Effects
PublisherNova Science Publishers, Inc.
Pages41-60
Number of pages20
ISBN (Electronic)9781536169928
StatePublished - 1 Jan 2020

Fingerprint

Dive into the research topics of 'Clozapine treatment for negative signs and cognitive impairment in schizophrenia'. Together they form a unique fingerprint.

Cite this